Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05859776 · ClinicalTrials.gov registry record · Phase 1
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by AsclepiX Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT05859776 is a Phase 1 study of Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by AsclepiX Therapeutics. The registered enrollment target is 15 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05859776, a Phase 1 study of Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by AsclepiX Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it aims to answer are: * Safety of the maximum tolerable dose of AXT107 * Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.
Conditions Studied
Interventions
- DRUG AXT107 Low Dose
- DRUG AXT107 Mid Dose
- DRUG AXT107 High Dose
Study Locations (4)
Massachusetts
- New England Retina Consultants - Springfield
Missouri
- The Retina Institue - St Louis
North Carolina
- Asheville Eye Associates - Asheville
Pennsylvania
- Erie Retina Research - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2025-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05859776
The ClinicalTrials.gov registry entry for NCT05859776 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is AsclepiX Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which AXT107 Low Dose is the first listed.
NCT05859776 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05859776 about?
NCT05859776 is a clinical study titled "Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)". The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it aims to answer are: * Safety of the maximum tolerable dose of AXT107 * Bioactivity and duration of action of AXT107 injected suprachoroidally Particip...
What is the current status of trial NCT05859776?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-12-19. Estimated completion is 2025-05.
What conditions does trial NCT05859776 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT05859776?
The interventions under investigation include: AXT107 Low Dose (DRUG), AXT107 Mid Dose (DRUG), AXT107 High Dose (DRUG).
Who is sponsoring clinical trial NCT05859776?
This trial is sponsored by AsclepiX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05859776 being conducted?
This trial has 4 study locations across Massachusetts, Missouri, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
COMPLETED · Phase 1
-
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.